Efficacy and safety of lebrikizumab at 16 weeks: pooled analyses from ADvocate1 and ADvocate2 phase III trials in patients with moderate-to-severe atopic dermatitis

被引：0

作者：

Warren, Richard B. ^{[1
]}

Silverberg, Jonathan I.

Guttman-Yassky, Emma ^{[2
]}

Thaci, Diamant ^{[3
]}

Irvine, Alan ^{[4
]}

Gold, Linda Stein ^{[5
]}

Blauvelt, Andrew ^{[6
]}

Simpson, Eric L. ^{[7
]}

Chu, Chia-Yu ^{[8
,9
]}

Liu, Zhuqing T. ^{[10
]}

Lima, Renata Gontijo ^{[10
]}

Pillai, Sreekumar ^{[10
]}

Garcia Gil, Esther ^{[11
]}

Seneschal, Julien ^{[12
,13
]}

机构：

[1] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, England

[2] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA

[3] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany

[4] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland

[5] Henry Ford Hlth Syst, Dermatol Clin Res, Detroit, MI USA

[6] Oregon Med Res Ctr, Portland, OR USA

[7] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR USA

[8] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan

[9] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[10] Eli Lilly & Co, Indianapolis, IN USA

[11] Almirall SA, Barcelona, Spain

[12] Univ Bordeaux, Dept Dermatol, Bordeaux, France

[13] Hosp St Andre, Natl Reference Ctr Rare Skin disorders, Dept Dermatol & Pediat Dermatol, Bordeaux, France

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷

关键词：

D O I：

10.1093/bjd/ljad113.112

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P84

引用

页数：1

共 50 条

[1] EVOLUTION OF EASI RESPONSE WITH LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO- SEVERE ATOPIC DERMATITIS: POOLED RESULTS FROM TWO PHASE 3 TRIALS (ADVOCATE1 AND ADVOCATE2) AT WEEK 16
Wollenberg, Andreas
Warren, Richard B.
Silverberg, Jonathan I.
Guttman-Yassky, Emma
Thaci, Diamant
Irvine, Alan D.
Gold, Linda Stein
Blauvelt, Andrew
Simpson, Eric L.
Chu, Chia-Yu
Liu, Zhuqing T.
Lima, Renata Gontijo
Pillai, Sreekumar
Gil, Esther Garcia
Seneschal, Julien
[J]. ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 53 - 53
[2] Efficacy and Safety of Lebrikizumab in moderate to severe atopic Dermatitis: Results of two randomized, double-blind, placebo-controlled phase III Studies (ADvocate1 and ADvocate2) at 52 Weeks
Blauvelt, A.
Thyssen, J. P.
Guttman-Yassky, E.
Bieber, T.
Serra-Baldrich, E.
Simspon, E.
Rosmarin, D.
Diemert, S.
Elmaraghy, H.
Silverberg, J.
[J]. ALLERGOLOGIE, 2023, 46 (08) : 530 - 530
[3] Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials (ADvocate1 and ADvocate2)
Marquardt, Tzvetelina
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Serra-Baldrich, Esther
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Silverberg, Jonathan
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 62
[4] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Carrascosa, Jose Manuel
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Silverberg, Jonathan, I
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[5] Lebrikizumab treatment improves quality of life in patients with moderate-to-severe atopic dermatitis: results from two phase III randomized, double-blinded, placebo-controlled trials (ADvocate1 and ADvocate2)
Lio, Peter
Armstrong, April
Gutermuth, Jan
Nosbaum, Audrey
Sofen, Howard
Casillas, Marta
Pierce, Evangeline
Elmaraghy, Hany
Chen, Sherry
Thyssen, Jacob P.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E109 - E110
[6] Efficacy of Lebrikizumab in Patients with Atopic Dermatitis and Atopic Comorbidities: Pooled Results from 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
Volc, Sebastian
Sher, Ellen R.
Boguniewicz, Mark
Golant, Alexandra K.
de Bruin-Weller, Marjolein S.
Carrascosa, Jose-Manuel
Zhong, Jinglin
Dawson, Zach
Atwater, Amber Reck
Siu, Kimberly
Thyssen, Jacob P.
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 79 - 80
[7] Efficacy of Lebrikizumab in Patients With Atopic Dermatitis and Atopic Comorbidities: Pooled Results From Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
Sher, Ellen
Boguniewicz, Mark
Golant, Alexandra
Zhong, Jinglin
Atwater, Amber Reck
Dawson, Zach
Siu, Kimberly
De Bruin-Weller, Marjolein
Carrascosa, Jose-Manuel
Thyssen, Jacob
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB148 - AB148
[8] Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
Simpson, Eric
Fernandez-Penas, Pablo
de Bruin-Weller, Marjolein
Lio, Peter A.
Chu, Chia-Yu
Ezzedine, Khaled
Agell, Helena
Casillas, Marta
Ding, Yuxin
Yang, Fan Emily
Pierce, Evangeline
Bieber, Thomas
[J]. ADVANCES IN THERAPY, 2024,
[9] Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis
Guttman-Yassky, Emma
Weidinger, Stephan
Simpson, Eric
Gooderham, Melinda
Irvine, Alan
Spelman, Lynda
Silverberg, Jonathan
Elmaraghy, Hany
DeLuca-Carter, Louise
Piruzeli, Maria Lucia Buziqui
Hu, Chaoran
Yang, Fan Emily
Pierce, Evangeline
Bardolet, Laia
Thaci, Diamant
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II3 - II4
[10] Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: data from eight trials
Gold, Linda Stein
Thaci, Diamant
Thyssen, Jacob P.
Gooderham, Melinda
Laquer, Vivian
Natalie, Chitra R.
Zhao, Fangyi
Meskimen, Eric
ElMaraghy, Hany
Montmayeur, Sonia
Jimenez, Gemma
de Bruin-Weller, Marjolein
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188

← 1 2 3 4 5 →